CAR-T cell therapy targeting BCMA and GPRC5D for advanced plasma cell cancers
Part of Cancer clinical trials.
This trial is testing a new type of cell therapy that uses your own immune cells (called CAR-T cells) to fight your cancer. The cells are modified to attack two specific targets on your cancer cells (BCMA and GPRC5D) to potentially improve treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a plasma cell cancer (like multiple myeloma) that has not responded to treatment or has come back.
- Your cancer cells must test positive for at least one of two specific proteins (BCMA or GPRC5D).
- You must have had at least two prior lines of treatment for this disease.
- Your cancer must have progressed within 12 months after your last treatment, or you must be resistant to both immunomodulatory drugs and proteasome inhibitors.
- You need to be between 18 and 75 years old, with a reasonable level of daily function (ECOG 0-2).
- Your organ function must be adequate, including heart, liver, kidney, and lungs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to attack cancer cells that have certain markers (CD19 or BCMA). It is for people with blood cancers like multiple myeloma or certain lymphomas that have not responded to multiple prior treatments. The goal is to see if this treatment can help when other options have failed.
This study is testing a new type of cell therapy (called CAR-T) that uses your own immune cells to attack the cancer cells in plasma cell tumors. It is designed for patients with multiple myeloma, plasma cell leukemia, plasmacytoma, or amyloidosis that has returned or not responded to standard treatments.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Hear when a new Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.